8-K: Matinas BioPharma Trading Halted on NYSE American Due to Low Share Price, Reverse Stock Split Planned

Matinas BioPharma's stock trading was halted by the NYSE American due to its low price, and the company plans a 1-for-50 reverse stock split to regain compliance.

Summary

• Matinas BioPharma Holdings, Inc. received notice on August 27, 2024, that trading of its common stock was halted by the NYSE American due to its low trading price.
• The trading halt is expected to remain in effect until after the company completes a reverse stock split.
• The company's Board of Directors previously approved a 1-for-50 reverse stock split.
• The reverse stock split will be effective at 5:00 PM EST on August 30, 2024.
• Trading on a split-adjusted basis is expected to begin when the market opens on September 3, 2024.
• Resumption of trading on the NYSE American is subject to exchange approval following the reverse stock split.
• The exchange could maintain the trading halt or suspend trading and delist the stock if the post-split price does not meet the exchange's requirements.

Sentiment

Score: 3

Explanation: The trading halt and need for a reverse stock split indicate significant negative pressure on the company's stock. While the company is taking action, the situation is concerning.

Positives

• The company is taking action with a reverse stock split to address the low share price and regain compliance with NYSE American listing requirements.

Negatives

• The trading halt indicates a significant issue with the company's stock price.
• There is a risk that the NYSE American could maintain the trading halt or delist the stock if the post-split price does not meet requirements.

Risks

• The NYSE American could maintain the trading halt even after the reverse stock split.
• There is a risk of the stock being delisted if the post-split price does not meet the exchange's minimum requirements.
• The reverse stock split may not be sufficient to permanently increase the stock price.

Future Outlook

The company anticipates that trading will resume on the NYSE American following the implementation of the reverse stock split, subject to exchange approval. However, the exchange could maintain the trading halt or delist the stock if the post-split price does not meet requirements.

Management Comments

• The company expects the trading halt to remain in effect until after the reverse stock split is completed.
• The company anticipates that trading will resume on the NYSE American following the implementation of the reverse stock split.

Industry Context

Reverse stock splits are a common action for companies facing low share prices to maintain listing compliance on major exchanges. This action is not uncommon in the biotech sector, where stock prices can be volatile.

Comparison to Industry Standards

• Many biotech companies with low share prices have implemented reverse stock splits to avoid delisting.
• The 1-for-50 ratio is a relatively high ratio, indicating a significant drop in share price.
• Other companies such as Agenus and Cassava Sciences have also recently undertaken reverse stock splits to maintain listing compliance.

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they own due to the reverse stock split.
• The reverse stock split may impact the perceived value of the company.
• The trading halt and potential delisting could negatively impact investor confidence.

Next Steps

• The company will complete the reverse stock split on August 30, 2024.
• The company will seek approval from the NYSE American to resume trading.
• The company will monitor the post-split stock price to ensure compliance with listing requirements.

Key Dates

Keywords

reverse stock split, trading halt, NYSE American, stock price, delisting, Matinas BioPharma